Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth

Restall C, Doherty J, Liu HB, Genovese R, Paiman L, Byron KA, Anderson RL, Dear AE

(2009), Int J Cancer, 125(2), 483-7

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

Prince HM, Hönemann D, Spencer A, Rizzieri DA, Stadtmauer EA, Roberts AW, Bahlis N, Tricot G, Bell B, Demarini DJ, Benjamin Suttle A, Baker KL, Pandite LN

(2009), Blood, 113(19), 4819-20

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, et al; IMWG

(2009), Leukemia, 23(10), 1716-30

A shear gradient-dependent platelet aggregation mechanism drives thrombus formation

Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP

(2009), Nat Med, 15(6), 665-73

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM

(2009), Leukemia, 23(11), 2147-52

Glycoprotein Ibalpha inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism

McEwan PA, Andrews RK, Emsley J

(2009), Blood, 114(23), 4883-5

Specific function of phosphoinositide 3-kinase beta in the control of DNA replication

Marqués M, Kumar A, Poveda AM, Zuluaga S, Hernández C, Jackson S, Pasero P, Carrera AC

(2009), Proc Natl Acad Sci USA, 106(18), 7525-30

The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression

Liu HB, Voso MT, Gumiero D, Duong J, McKendrick JJ, Dear AE

(2009), Int J Oncol, 34(2), 573-9

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

Liu H, Dear AE, Knudsen LB, Simpson RW

(2009), J Endocrinol, 201(1), 59-66

The identification of a calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2

Lai ZW, Lew RA, Yarski MA, Mu FT, Andrews RK, Smith AI

(2009), Endocrinology, 150(5), 2376-81

Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets

Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP

(2009), J Biol Chem, 284(49), 33763-72

Dynamics of platelet thrombus formation

Jackson SP, Nesbitt WS, Westein E

(2009), J Thromb Haemost, 7, Suppl 1, 17-20

Protease-activated receptors as targets for antiplatelet therapy

Hamilton JR

(2009), Blood Rev, 23(2), 61-5

Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice

Hamilton JR, Cornelissen I, Mountford JK, Coughlin SR

(2009), Atherosclerosis, 205(2), 427-32

Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation

Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, Olieslagers S, Chrzanowska-Wodnicka MB, Lillian R, Schoenwaelder S, Koyasu S, Sage SO, Jackson SP, Heemskerk JW

(2009), J Biol Chem, 284(49), 33750-62

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma

Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM

(2009), Br J Haematol, 147(1), 97-101

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma

Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, Horvath N, Roberts AW, Prince HM, Hertzberg M, McLean CA, Spencer A

(2009), Clin Cancer Res, 15(2), 714-22

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

Brown RD, Spencer A, Ho PJ, Kennedy N, Kabani K, Yang S, Sze DM, Aklilu E, Gibson J, Joshua DE

(2009), Leuk Lymphoma, 50(11), 1860-4

Is thrombin the problem or (dis)solution?

Arthur JF, Jackson SP

(2009), Blood, 113(24), 6046-7

Measuring soluble platelet glycoprotein VI in human plasma by ELISA

Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK

(2009), Platelets, 20(3), 143-9

548 549 550 551 552